

Patrick Wen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10394858/publications.pdf>

Version: 2024-02-01

37
papers

1,907
citations

759233

12
h-index

552781

26
g-index

40
all docs

40
docs citations

40
times ranked

2171
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. <i>Investigational New Drugs</i> , 2005, 23, 357-361.	2.6	402
2	Molecular targeted therapy of glioblastoma. <i>Cancer Treatment Reviews</i> , 2019, 80, 101896.	7.7	386
3	Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. <i>Clinical Cancer Research</i> , 2005, 11, 7841-7850.	7.0	238
4	Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. <i>Neuro-Oncology</i> , 2014, 16, 829-840.	1.2	198
5	Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. <i>Nature Medicine</i> , 1997, 3, 437-442.	30.7	195
6	Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. <i>Nature Medicine</i> , 1997, 3, 1145-1149.	30.7	158
7	Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. <i>Investigational New Drugs</i> , 2004, 22, 427-435.	2.6	84
8	<i>In Vivo</i> Replication-Deficient Adenovirus Vector-Mediated Transduction of the Cytosine Deaminase Gene Sensitizes Glioma Cells to 5-Fluorocytosine. <i>Human Gene Therapy</i> , 1996, 7, 713-720.	2.7	77
9	Phase I Trial of Tipifarnib in Patients With Recurrent Malignant Glioma Taking Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 6647-6656.	1.6	61
10	Use of the immunotoxin N901-blocked ricin in patients with small-cell lung cancer. <i>International Journal of Cancer</i> , 1994, 57, 57-59.	5.1	24
11	Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02. <i>Journal of Neuro-Oncology</i> , 2018, 136, 79-86.	2.9	21
12	A 3-dimensional DTI MRI-based model of GBM growth and response to radiation therapy. <i>International Journal of Oncology</i> , 2016, 49, 1081-1087.	3.3	12
13	ACTR-31. PHASE 1 STUDY OF AG-881, AN INHIBITOR OF MUTANT IDH1 AND IDH2: RESULTS FROM THE RECURRENT/PROGRESSIVE GLIOMA POPULATION. <i>Neuro-Oncology</i> , 2018, 20, vi18-vi18.	1.2	12
14	ACTR-30. PHASE 1B/2 STUDY TO ASSESS THE CLINICAL EFFECTS OF PAMIPARIB (BGB-290) IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY GLIOBLASTOMA (GBM). <i>Neuro-Oncology</i> , 2018, 20, vi17-vi18.	1.2	6
15	ACTR-14. PHASE I STUDY OF AZD1775 WITH RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) AND EVALUATION OF INTRATUMORAL DRUG DISTRIBUTION (IDD) IN PATIENTS WITH RECURRENT GBM. <i>Neuro-Oncology</i> , 2018, 20, vi13-vi14.	1.2	6
16	RBTT-03. A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PERIOPERATIVE STUDY OF AG-120 (IVOSIDENIB) AND AG-881 IN PATIENTS WITH RECURRENT, NONENHANCING, IDH1-MUTANT, LOW-GRADE GLIOMA. <i>Neuro-Oncology</i> , 2018, 20, vi234-vi234.	1.2	4
17	RBTT-01. RANDOMIZED PHASE 2 OPEN LABEL STUDY OF NIVOLUMAB PLUS STANDARD DOSE BEVACIZUMAB VERSUS NIVOLUMAB PLUS LOW DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi234-vi234.	1.2	4
18	PDTM-06. ALK AMPLIFICATION AND REARRANGEMENTS ARE RECURRENT TARGETABLE EVENTS IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi204-vi205.	1.2	3

#	ARTICLE	IF	CITATIONS
19	ACTR-34. INTEGRATED CLINICAL EXPERIENCE WITH ONC201 IN PREVIOUSLY-TREATED H3 K27M-MUTANT GLIOMA PATIENTS. <i>Neuro-Oncology</i> , 2018, 20, vi19-vi19.	1.2	3
20	ACTR-15. SAFETY AND PRELIMINARY ACTIVITY OF PT2385, A FIRST-IN-CLASS HIF2-ALPHA INHIBITOR, PLANNED INTERIM ANALYSIS OF AN OPEN LABEL, SINGLE-ARM PHASE II STUDY IN PATIENTS WITH RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi14-vi14.	1.2	3
21	ATIM-19. RESULTS OF THE GLOBE STUDY: A PHASE 3, RANDOMIZED, CONTROLLED, DOUBLE-ARM, OPEN-LABEL, MULTI-CENTER STUDY OF VB-111 COMBINED WITH BEVACIZUMAB VS. BEVACIZUMAB MONOTHERAPY IN PATIENTS WITH RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi4-vi5.	1.2	3
22	RARE-24. OBJECTIVE RESPONSE AND CLINICAL BENEFIT IN RECURRENT EPENDYMOMA IN ADULTS: FINAL REPORT OF CERN 08-02: A PHASE II STUDY OF DOSE-DENSE TEMOZOLOMIDE AND LAPATINIB. <i>Neuro-Oncology</i> , 2018, 20, vi241-vi241.	1.2	2
23	Clinical Importance of CDKN2A Loss and Monosomy 10 in Pilocytic Astrocytoma. <i>Cureus</i> , 2019, 11, e4726.	0.5	2
24	ACTR-18. PHASE II TRIAL OF TEMOZOLOMIDE AND TRC 102, BASE EXCISION REPAIR INHIBITOR, IN BEVACIZUMAB NAÏVE GLIOBLASTOMA AT FIRST RECURRENCE. <i>Neuro-Oncology</i> , 2018, 20, vi15-vi15.	1.2	1
25	ACTR-17. EVOPHOSPHAMIDE (TH-302) FOR RECURRENT GBM FOLLOWING BEVACIZUMAB FAILURE, FINAL RESULTS OF A MULTICENTER PHASE II STUDY. <i>Neuro-Oncology</i> , 2018, 20, vi14-vi15.	1.2	1
26	The Identification of Hypercoagulable Markers in Patients with Malignant Gliomas and Venous Thromboembolism.. <i>Blood</i> , 2006, 108, 4097-4097.	1.4	1
27	AT-36PANOBINOSTAT IN COMBINATION WITH BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA AND ANAPLASTIC GLIOMA. <i>Neuro-Oncology</i> , 2014, 16, v16-v16.	1.2	0
28	NIMG-31. RESIDUAL ENHANCING TUMOR VOLUME IS A STRONG PROGNOSTIC BIOMARKER FOR SURVIVAL IN BOTH NEWLY DIAGNOSED AND RECURRENT GBM REGARDLESS OF THERAPY: EVIDENCE FROM 1,535 PATIENTS IN SINGLE AND MULTICENTER TRIALS. <i>Neuro-Oncology</i> , 2016, 18, vi131-vi131.	1.2	0
29	PDCT-13. GUIDELINES FOR RESPONSE ASSESSMENT IN MEDULLOBLASTOMA AND OTHER LEPTOMENINGEAL SEEDING TUMORS: A REPORT FROM THE RESPONSE ASSESSMENT IN PEDIATRIC NEURO-ONCOLOGY (RAPNO) WORKING GROUP. <i>Neuro-Oncology</i> , 2016, 18, vi148-vi149.	1.2	0
30	INN-13. ALLELE: A CONSORTIUM FOR PROSPECTIVE GENOMICS AND FUNCTIONAL DIAGNOSTICS TO GUIDE PATIENT CARE AND TRIAL ANALYSIS IN NEWLY-DIAGNOSED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi140-vi141.	1.2	0
31	PATH-08. THE IVY GLIOBLASTOMA PATIENT ATLAS - A NOVEL CLINICAL AND RADIO-GENOMICS RESOURCE FOR EARLY PHASE CLINICAL TRIAL DESIGN AND INTERPRETATION. <i>Neuro-Oncology</i> , 2018, 20, vi159-vi159.	1.2	0
32	ATIM-21. UPDATED RESULTS OF A PHASE I TRIAL OF ANTI-LAG-3 OR ANTI-CD137 ALONE AND IN COMBINATION WITH ANTI-PD-1 IN PATIENTS WITH RECURRENT GBM. <i>Neuro-Oncology</i> , 2018, 20, vi5-vi5.	1.2	0
33	ATIM-29. NRG BN002: SAFETY DATA FROM A PHASE I STUDY OF IPILIMUMAB (IPI), NIVOLUMAB (NIVO), AND THE COMBINATION FOR NEWLY DIAGNOSED GLIOBLASTOMA (GBM). <i>Neuro-Oncology</i> , 2018, 20, vi7-vi7.	1.2	0
34	ACTR-51. PHASE 2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND CLINICAL ACTIVITY OF PI3K/MTOR INHIBITOR GDC-0084 GIVEN TO GLIOBLASTOMA (GBM) PATIENTS WITH UNMETHYLATED O6-METHYLGUANINE-METHYLTRANSFERASE PROMOTER STATUS. <i>Neuro-Oncology</i> , 2018, 20, vi23-vi23.	1.2	0
35	PATH-16. MOLECULAR PATHOLOGY AND CLINICAL CHARACTERISTICS OF MMR DEFICIENCY (MMRd) IN DIFFUSE GLIOMAS. <i>Neuro-Oncology</i> , 2018, 20, vi161-vi161.	1.2	0
36	NIMG-68. MRI CHANGES IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS TREATED AS PART OF A PHASE II TRIAL WITH BAVITUXIMAB, RADIATION, AND TEMOZOLOMIDE. <i>Neuro-Oncology</i> , 2018, 20, vi191-vi191.	1.2	0

#	ARTICLE	IF	CITATIONS
37	CTNI-27. SINGLE AGENT ACTIVITY OF ONC201 IN NON-MIDLINE H3 K27M-MUTANT DIFFUSE GLIOMAS. Neuro-Oncology, 2021, 23, vi65-vi65.	1.2	0